Low Levels of Natural Anti-α-N-Acetylgalactosamine (Tn) Antibodies Are Associated With COVID-19

Human serum contains large amounts of anti-carbohydrate antibodies, some of which may recognize epitopes on viral glycans Here, we tested the hypothesis that such antibodies may confer protection against COVID-19 so that patients would be preferentially found among people with low amounts of specific anti-carbohydrate antibodies since individual repertoires vary considerably After selecting glycan epitopes commonly represented in the human anti-carbohydrate antibody repertoire that may also be expressed on viral glycans, plasma levels of the corresponding antibodies were determined by ELISA in 88 SARS-CoV-2 infected individuals, including 13 asymptomatic, and in 82 non-infected controls We observed that anti-Tn antibodies levels were significantly lower in patients as compared to non-infected individuals This was not observed for any of the other tested carbohydrate epitopes, including anti-alphaGal antibodies used as a negative control since the epitope cannot be synthesized by humans Owing to structural homologies with blood groups A and B antigens, we also observed that anti-Tn and anti-alphaGal antibodies levels were lower in blood group A and B, respectively Analyses of correlations between anti-Tn and the other anti-carbohydrates tested revealed divergent patterns of correlations between patients and controls, suggesting qualitative differences in addition to the quantitative difference Furthermore, anti-Tn levels correlated with anti-S protein levels in the patients' group, suggesting that anti-Tn might contribute to the development of the specific antiviral response Overall, this first analysis allows to hypothesize that natural anti-Tn antibodies might be protective against COVID-19